Eintrag weiter verarbeiten
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
Gespeichert in:
| Zeitschriftentitel: | Hepatology Communications |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , |
| In: | Hepatology Communications, 2, 2018, 5, S. 595-606 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
George, Jacob Burnevich, Eduard Sheen, I‐Shyan Heo, Jeong Kinh, Nguyen Van Tanwandee, Tawesak Cheng, Pin‐Nan Kim, Do Young Tak, Won Young Kizhlo, Svetlana Zhdanov, Konstantin Isakov, Vasily Liang, Liwen Lindore, Pauline Ginanni, Joy Nguyen, Bach‐Yen Wahl, Janice Barr, Eliav Robertson, Michael Ingravallo, Paul Talwani, Rohit George, Jacob Burnevich, Eduard Sheen, I‐Shyan Heo, Jeong Kinh, Nguyen Van Tanwandee, Tawesak Cheng, Pin‐Nan Kim, Do Young Tak, Won Young Kizhlo, Svetlana Zhdanov, Konstantin Isakov, Vasily Liang, Liwen Lindore, Pauline Ginanni, Joy Nguyen, Bach‐Yen Wahl, Janice Barr, Eliav Robertson, Michael Ingravallo, Paul Talwani, Rohit |
|---|---|
| author |
George, Jacob Burnevich, Eduard Sheen, I‐Shyan Heo, Jeong Kinh, Nguyen Van Tanwandee, Tawesak Cheng, Pin‐Nan Kim, Do Young Tak, Won Young Kizhlo, Svetlana Zhdanov, Konstantin Isakov, Vasily Liang, Liwen Lindore, Pauline Ginanni, Joy Nguyen, Bach‐Yen Wahl, Janice Barr, Eliav Robertson, Michael Ingravallo, Paul Talwani, Rohit |
| spellingShingle |
George, Jacob Burnevich, Eduard Sheen, I‐Shyan Heo, Jeong Kinh, Nguyen Van Tanwandee, Tawesak Cheng, Pin‐Nan Kim, Do Young Tak, Won Young Kizhlo, Svetlana Zhdanov, Konstantin Isakov, Vasily Liang, Liwen Lindore, Pauline Ginanni, Joy Nguyen, Bach‐Yen Wahl, Janice Barr, Eliav Robertson, Michael Ingravallo, Paul Talwani, Rohit Hepatology Communications Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection Hepatology |
| author_sort |
george, jacob |
| spelling |
George, Jacob Burnevich, Eduard Sheen, I‐Shyan Heo, Jeong Kinh, Nguyen Van Tanwandee, Tawesak Cheng, Pin‐Nan Kim, Do Young Tak, Won Young Kizhlo, Svetlana Zhdanov, Konstantin Isakov, Vasily Liang, Liwen Lindore, Pauline Ginanni, Joy Nguyen, Bach‐Yen Wahl, Janice Barr, Eliav Robertson, Michael Ingravallo, Paul Talwani, Rohit 2471-254X 2471-254X Ovid Technologies (Wolters Kluwer Health) Hepatology http://dx.doi.org/10.1002/hep4.1177 <jats:p>The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from Asia‐Pacific countries and Russia. In this phase 3, randomized, placebo‐controlled, double‐blind study, treatment‐naive participants with HCV genotype (GT) 1, 4, or 6 infection were randomized to EBR 50 mg/GZR 100 mg (immediate‐treatment group [ITG]) or placebo (deferred‐treatment group [DTG]) once daily for 12 weeks (Protocol PN‐5172‐067, NCT02251990). The primary efficacy variable was a nonrandomized comparison of sustained virologic response at 12 weeks after the end of therapy (SVR12) for the ITG with a historical control. The primary safety outcome was a randomized comparison between the ITG and DTG. Three hundred thirty‐seven participants were randomized to the ITG (n = 251) or DTG (n = 86); 199 (59.2%) participants were Asian, and 250 (74.4%) had HCV GT1b infection. Overall, 232/250 (92.8%) participants in the ITG achieved SVR12 (97.5% confidence interval, 89.1, 96.5). Of the 18 participants who failed to attain SVR12, 1 was lost to follow‐up and 17 had virologic failure, 13 of whom had HCV GT6 infection. The incidence of adverse events was similar between participants receiving EBR/GZR and placebo (50.8% versus 51.2%; difference, −0.3%; 95% confidence interval, −12.3, 11.9). <jats:italic toggle="yes">Conclusion:</jats:italic> EBR/GZR for 12 weeks provides an effective and well‐tolerated regimen for chronic HCV GT1 infection in treatment‐naive people from Asia‐Pacific countries and Russia, particularly for the large population with GT1b infection. EBR/GZR is not recommended for the treatment of individuals with HCV GT6 infection. (<jats:italic toggle="yes">Hepatology Communications</jats:italic> 2018;2:595‐606)</jats:p> Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection Hepatology Communications |
| doi_str_mv |
10.1002/hep4.1177 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9oZXA0LjExNzc |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9oZXA0LjExNzc |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2018 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2018 |
| issn |
2471-254X |
| issn_str_mv |
2471-254X |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
george2018elbasvirgrazoprevirinasiapacificrussianparticipantswithchronichepatitiscvirusgenotype14or6infection |
| publishDateSort |
2018 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Hepatology Communications |
| source_id |
49 |
| title |
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_unstemmed |
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_full |
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_fullStr |
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_full_unstemmed |
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_short |
Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_sort |
elbasvir/grazoprevir in asia‐pacific/russian participants with chronic hepatitis c virus genotype 1, 4, or 6 infection |
| topic |
Hepatology |
| url |
http://dx.doi.org/10.1002/hep4.1177 |
| publishDate |
2018 |
| physical |
595-606 |
| description |
<jats:p>The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from Asia‐Pacific countries and Russia. In this phase 3, randomized, placebo‐controlled, double‐blind study, treatment‐naive participants with HCV genotype (GT) 1, 4, or 6 infection were randomized to EBR 50 mg/GZR 100 mg (immediate‐treatment group [ITG]) or placebo (deferred‐treatment group [DTG]) once daily for 12 weeks (Protocol PN‐5172‐067, NCT02251990). The primary efficacy variable was a nonrandomized comparison of sustained virologic response at 12 weeks after the end of therapy (SVR12) for the ITG with a historical control. The primary safety outcome was a randomized comparison between the ITG and DTG. Three hundred thirty‐seven participants were randomized to the ITG (n = 251) or DTG (n = 86); 199 (59.2%) participants were Asian, and 250 (74.4%) had HCV GT1b infection. Overall, 232/250 (92.8%) participants in the ITG achieved SVR12 (97.5% confidence interval, 89.1, 96.5). Of the 18 participants who failed to attain SVR12, 1 was lost to follow‐up and 17 had virologic failure, 13 of whom had HCV GT6 infection. The incidence of adverse events was similar between participants receiving EBR/GZR and placebo (50.8% versus 51.2%; difference, −0.3%; 95% confidence interval, −12.3, 11.9). <jats:italic toggle="yes">Conclusion:</jats:italic> EBR/GZR for 12 weeks provides an effective and well‐tolerated regimen for chronic HCV GT1 infection in treatment‐naive people from Asia‐Pacific countries and Russia, particularly for the large population with GT1b infection. EBR/GZR is not recommended for the treatment of individuals with HCV GT6 infection. (<jats:italic toggle="yes">Hepatology Communications</jats:italic> 2018;2:595‐606)</jats:p> |
| container_issue |
5 |
| container_start_page |
595 |
| container_title |
Hepatology Communications |
| container_volume |
2 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348158719688709 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:06:41.797Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Elbasvir%2Fgrazoprevir+in+Asia%E2%80%90Pacific%2FRussian+participants+with+chronic+hepatitis+C+virus+genotype+1%2C+4%2C+or+6+infection&rft.date=2018-05-01&genre=article&issn=2471-254X&volume=2&issue=5&spage=595&epage=606&pages=595-606&jtitle=Hepatology+Communications&atitle=Elbasvir%2Fgrazoprevir+in+Asia%E2%80%90Pacific%2FRussian+participants+with+chronic+hepatitis+C+virus+genotype+1%2C+4%2C+or+6+infection&aulast=Talwani&aufirst=Rohit&rft_id=info%3Adoi%2F10.1002%2Fhep4.1177&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348158719688709 |
| author | George, Jacob, Burnevich, Eduard, Sheen, I‐Shyan, Heo, Jeong, Kinh, Nguyen Van, Tanwandee, Tawesak, Cheng, Pin‐Nan, Kim, Do Young, Tak, Won Young, Kizhlo, Svetlana, Zhdanov, Konstantin, Isakov, Vasily, Liang, Liwen, Lindore, Pauline, Ginanni, Joy, Nguyen, Bach‐Yen, Wahl, Janice, Barr, Eliav, Robertson, Michael, Ingravallo, Paul, Talwani, Rohit |
| author_facet | George, Jacob, Burnevich, Eduard, Sheen, I‐Shyan, Heo, Jeong, Kinh, Nguyen Van, Tanwandee, Tawesak, Cheng, Pin‐Nan, Kim, Do Young, Tak, Won Young, Kizhlo, Svetlana, Zhdanov, Konstantin, Isakov, Vasily, Liang, Liwen, Lindore, Pauline, Ginanni, Joy, Nguyen, Bach‐Yen, Wahl, Janice, Barr, Eliav, Robertson, Michael, Ingravallo, Paul, Talwani, Rohit, George, Jacob, Burnevich, Eduard, Sheen, I‐Shyan, Heo, Jeong, Kinh, Nguyen Van, Tanwandee, Tawesak, Cheng, Pin‐Nan, Kim, Do Young, Tak, Won Young, Kizhlo, Svetlana, Zhdanov, Konstantin, Isakov, Vasily, Liang, Liwen, Lindore, Pauline, Ginanni, Joy, Nguyen, Bach‐Yen, Wahl, Janice, Barr, Eliav, Robertson, Michael, Ingravallo, Paul, Talwani, Rohit |
| author_sort | george, jacob |
| container_issue | 5 |
| container_start_page | 595 |
| container_title | Hepatology Communications |
| container_volume | 2 |
| description | <jats:p>The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from Asia‐Pacific countries and Russia. In this phase 3, randomized, placebo‐controlled, double‐blind study, treatment‐naive participants with HCV genotype (GT) 1, 4, or 6 infection were randomized to EBR 50 mg/GZR 100 mg (immediate‐treatment group [ITG]) or placebo (deferred‐treatment group [DTG]) once daily for 12 weeks (Protocol PN‐5172‐067, NCT02251990). The primary efficacy variable was a nonrandomized comparison of sustained virologic response at 12 weeks after the end of therapy (SVR12) for the ITG with a historical control. The primary safety outcome was a randomized comparison between the ITG and DTG. Three hundred thirty‐seven participants were randomized to the ITG (n = 251) or DTG (n = 86); 199 (59.2%) participants were Asian, and 250 (74.4%) had HCV GT1b infection. Overall, 232/250 (92.8%) participants in the ITG achieved SVR12 (97.5% confidence interval, 89.1, 96.5). Of the 18 participants who failed to attain SVR12, 1 was lost to follow‐up and 17 had virologic failure, 13 of whom had HCV GT6 infection. The incidence of adverse events was similar between participants receiving EBR/GZR and placebo (50.8% versus 51.2%; difference, −0.3%; 95% confidence interval, −12.3, 11.9). <jats:italic toggle="yes">Conclusion:</jats:italic> EBR/GZR for 12 weeks provides an effective and well‐tolerated regimen for chronic HCV GT1 infection in treatment‐naive people from Asia‐Pacific countries and Russia, particularly for the large population with GT1b infection. EBR/GZR is not recommended for the treatment of individuals with HCV GT6 infection. (<jats:italic toggle="yes">Hepatology Communications</jats:italic> 2018;2:595‐606)</jats:p> |
| doi_str_mv | 10.1002/hep4.1177 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9oZXA0LjExNzc |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2018 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2018 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 2471-254X |
| issn_str_mv | 2471-254X |
| language | English |
| last_indexed | 2024-03-01T18:06:41.797Z |
| match_str | george2018elbasvirgrazoprevirinasiapacificrussianparticipantswithchronichepatitiscvirusgenotype14or6infection |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | 595-606 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Hepatology Communications |
| source_id | 49 |
| spelling | George, Jacob Burnevich, Eduard Sheen, I‐Shyan Heo, Jeong Kinh, Nguyen Van Tanwandee, Tawesak Cheng, Pin‐Nan Kim, Do Young Tak, Won Young Kizhlo, Svetlana Zhdanov, Konstantin Isakov, Vasily Liang, Liwen Lindore, Pauline Ginanni, Joy Nguyen, Bach‐Yen Wahl, Janice Barr, Eliav Robertson, Michael Ingravallo, Paul Talwani, Rohit 2471-254X 2471-254X Ovid Technologies (Wolters Kluwer Health) Hepatology http://dx.doi.org/10.1002/hep4.1177 <jats:p>The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from Asia‐Pacific countries and Russia. In this phase 3, randomized, placebo‐controlled, double‐blind study, treatment‐naive participants with HCV genotype (GT) 1, 4, or 6 infection were randomized to EBR 50 mg/GZR 100 mg (immediate‐treatment group [ITG]) or placebo (deferred‐treatment group [DTG]) once daily for 12 weeks (Protocol PN‐5172‐067, NCT02251990). The primary efficacy variable was a nonrandomized comparison of sustained virologic response at 12 weeks after the end of therapy (SVR12) for the ITG with a historical control. The primary safety outcome was a randomized comparison between the ITG and DTG. Three hundred thirty‐seven participants were randomized to the ITG (n = 251) or DTG (n = 86); 199 (59.2%) participants were Asian, and 250 (74.4%) had HCV GT1b infection. Overall, 232/250 (92.8%) participants in the ITG achieved SVR12 (97.5% confidence interval, 89.1, 96.5). Of the 18 participants who failed to attain SVR12, 1 was lost to follow‐up and 17 had virologic failure, 13 of whom had HCV GT6 infection. The incidence of adverse events was similar between participants receiving EBR/GZR and placebo (50.8% versus 51.2%; difference, −0.3%; 95% confidence interval, −12.3, 11.9). <jats:italic toggle="yes">Conclusion:</jats:italic> EBR/GZR for 12 weeks provides an effective and well‐tolerated regimen for chronic HCV GT1 infection in treatment‐naive people from Asia‐Pacific countries and Russia, particularly for the large population with GT1b infection. EBR/GZR is not recommended for the treatment of individuals with HCV GT6 infection. (<jats:italic toggle="yes">Hepatology Communications</jats:italic> 2018;2:595‐606)</jats:p> Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection Hepatology Communications |
| spellingShingle | George, Jacob, Burnevich, Eduard, Sheen, I‐Shyan, Heo, Jeong, Kinh, Nguyen Van, Tanwandee, Tawesak, Cheng, Pin‐Nan, Kim, Do Young, Tak, Won Young, Kizhlo, Svetlana, Zhdanov, Konstantin, Isakov, Vasily, Liang, Liwen, Lindore, Pauline, Ginanni, Joy, Nguyen, Bach‐Yen, Wahl, Janice, Barr, Eliav, Robertson, Michael, Ingravallo, Paul, Talwani, Rohit, Hepatology Communications, Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection, Hepatology |
| title | Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_full | Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_fullStr | Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_full_unstemmed | Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_short | Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| title_sort | elbasvir/grazoprevir in asia‐pacific/russian participants with chronic hepatitis c virus genotype 1, 4, or 6 infection |
| title_unstemmed | Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection |
| topic | Hepatology |
| url | http://dx.doi.org/10.1002/hep4.1177 |